Stockpolly
Search
VRCA · NASDAQ · Biotechnology

Verrica Pharmaceuticals (VRCA)

Commercializes YCANTH for molluscum while developing additional dermatology treatments.

$5.72
Pre-market+0.30 (+5.54%)
At close$5.42(+3.44%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue3245−2031314556
Cost of revenue0211101001111
Gross profit3−1935−2031213445
27521201811111112111418
Research & development755321222346
20171617161099981010
Selling & marketing002114000000
General & administrative201715151569000010
Other expenses0−180000000002
Operating income−24−23−19−15−21−11−822−7−10−13
−1−1−2−2−2−5−2−1−2−100
Interest income111000000000
Interest expense222222222100
Other non-operating income−1−3−1002−1−10000
Income before tax−25−25−20−17−23−16−1000−8−10−13
Net income from continuing operations−25−25−20−17−23−16−1000−8−10−13
Net income−25−25−20−17−23−16−1000−8−10−13
EPS, basic−$5.38−$5.31−$4.37−$3.70−$4.88−$2.41−$1.03$0.02−$0.03−$0.64−$0.45−$0.62
EPS, diluted−$5.38−$5.31−$4.37−$3.70−$4.88−$2.41−$1.03$0.02−$0.03−$0.64−$0.45−$0.62
Weighted average shares, basic555557999112121
Weighted average shares, diluted555557999112121
EBITDA−23−20−18−14−20−14−732−7−9−13
Depreciation & amortization000000000000
EBIT−23−21−18−15−20−14−822−7−10−13